REFLECT: Phase III Noninferiority Study of the Multikinase Inhibitor Lenvatinib vs Sorafenib as First-line Therapy in Unresectable Hepatocellular Carcinoma

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Lenvatinib demonstrated noninferior OS, significantly increased PFS, TTP, and ORR vs sorafenib with expected safety profile.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.15 MB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings